Table 2.
Tumor evaluation.
| Best Response to TKI (RECIST) | N (%) |
|---|---|
| For all patients | |
| Complete Response (CR) | 2 (7, 69%) |
| Partial Response (PR) | 8 (30, 77%) |
| Stability Disease (SD) | 12 (46, 15%) |
| Progression Disease (PD) | 4 (15, 38%) |
| Not available | 1 |
| DFSP without transformation | |
| Complete Response (CR) | 1 (5, 55%) |
| Partial Response (PR) | 7 (38, 89%) |
| Stability Disease (SD) | 8 (44, 45%) |
| Progression Disease (PD) | 2 (11, 11%) |
| DFPS with transformation | |
| Complete Response (CR) | 1 (11, 11%) |
| Partial Response (PR) | 1 (11, 11%) |
| Stability Disease (SD) | 4 (44, 45%) |
| Progression Disease (PD) | 2 (22, 22%) |
| Not available | 1 |
| Last known status | N (%) |
| No evidence of disease (NED) | 23 (85, 19%) |
| PR | 0 (0%) |
| SD with refusal of surgery | 1 (3, 70%) |
| PD with metastasis after complete resection (R0) | 1 (3, 70%) |
| PD before surgery | 2 (7, 41%) |